[go: up one dir, main page]

TNSN99145A1 - Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate - Google Patents

Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate

Info

Publication number
TNSN99145A1
TNSN99145A1 TNTNSN99145A TNSN99145A TNSN99145A1 TN SN99145 A1 TNSN99145 A1 TN SN99145A1 TN TNSN99145 A TNTNSN99145 A TN TNSN99145A TN SN99145 A TNSN99145 A TN SN99145A TN SN99145 A1 TNSN99145 A1 TN SN99145A1
Authority
TN
Tunisia
Prior art keywords
aminophenyle
furanyle
sulfonyle
isobutyle
benzyle
Prior art date
Application number
TNTNSN99145A
Other languages
English (en)
Inventor
Gordon Armitage Ian
David Searle Andrew
Singh Hardev
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TNSN99145A1 publication Critical patent/TNSN99145A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

-L'INVENTION PORTE SUR LE CALCIUM (3S) TETRAHYDRO-3-FURANYLE (1S,2R) -3-[[4-AMINOPHENYLE) SULFONYLE] ISOBUTYLE) AMINO]-1-BENZYLE-2- (PHOSPHONOOXY) PROPYLCARBAMATE, SUR LES PROCEDES POUR SA PREPARATION, ET SUR SON UTILISATION DANS LE TRAITEMENT DES MALADIES CAUSEES PAR LES RETROVIRUS.
TNTNSN99145A 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate TNSN99145A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9815567.4A GB9815567D0 (en) 1998-07-18 1998-07-18 Antiviral compound

Publications (1)

Publication Number Publication Date
TNSN99145A1 true TNSN99145A1 (fr) 2005-11-10

Family

ID=10835689

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99145A TNSN99145A1 (fr) 1998-07-18 1999-07-15 Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate

Country Status (47)

Country Link
US (3) US6514953B1 (fr)
EP (2) EP1240903A3 (fr)
JP (1) JP3437553B2 (fr)
KR (1) KR100694721B1 (fr)
CN (1) CN1188422C (fr)
AP (1) AP2001002039A0 (fr)
AR (1) AR019388A1 (fr)
AT (1) ATE229964T1 (fr)
AU (1) AU766056B2 (fr)
BG (1) BG105253A (fr)
BR (1) BRPI9912156B8 (fr)
CA (1) CA2337857C (fr)
CO (1) CO5090836A1 (fr)
CZ (1) CZ300447B6 (fr)
DE (1) DE69904600T2 (fr)
DK (1) DK1098898T3 (fr)
DZ (1) DZ2845A1 (fr)
EA (1) EA003191B1 (fr)
EE (1) EE200100038A (fr)
ES (1) ES2189450T3 (fr)
GB (1) GB9815567D0 (fr)
GC (1) GC0000105A (fr)
GE (1) GEP20033030B (fr)
GT (1) GT199900111A (fr)
HR (1) HRP20010046A2 (fr)
HU (1) HU229700B1 (fr)
ID (1) ID28070A (fr)
IL (1) IL140824A (fr)
IS (1) IS5808A (fr)
JO (1) JO2114B1 (fr)
MA (1) MA26660A1 (fr)
MY (1) MY122323A (fr)
NO (1) NO329676B1 (fr)
NZ (1) NZ509291A (fr)
OA (1) OA11706A (fr)
PA (1) PA8477801A1 (fr)
PE (1) PE20000869A1 (fr)
PL (1) PL195736B1 (fr)
PT (1) PT1098898E (fr)
SK (1) SK285311B6 (fr)
SV (1) SV1999000096A (fr)
TN (1) TNSN99145A1 (fr)
TR (1) TR200100111T2 (fr)
TW (1) TWI245770B (fr)
WO (1) WO2000004033A1 (fr)
YU (1) YU3401A (fr)
ZA (1) ZA200100417B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
HU228938B1 (hu) * 1999-10-06 2013-06-28 Us Government Hexahidrofuro[2,3-b]furán-3-il-N-{3-(1,3-benzodioxol-5-il-szulfonil)-(izobutil)-amino-1-benzil-2- -(hidroxi-propil)}-karbamát mint retrovírus proteáz gátló
HK1049656A1 (zh) 1999-10-08 2003-05-23 Smithkline Beecham Corporation Fab i抑制剂
DK1560584T3 (da) * 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
HRP20041113B1 (en) * 2002-04-26 2008-09-30 Gilead Sciences Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such
ES2518316T3 (es) * 2002-12-06 2014-11-05 Debiopharm International Sa Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia
CA2519429C (fr) 2003-03-17 2013-08-06 Affinium Pharmaceuticals, Inc. Compositions pharmaceutiques comportant des inhibiteurs de fab i et autres antibiotiques
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
WO2004096287A2 (fr) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Composes de phosphonate inhibiteurs de l'inosine monophosphate deshydrogenase
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
EA200501676A1 (ru) 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US20080234288A1 (en) * 2003-09-30 2008-09-25 Kenneth Alan Simmen Hcv Inhibiting Sulfonamides
US7427624B2 (en) 2003-10-24 2008-09-23 Gilead Sciences, Inc. Purine nucleoside phosphorylase inhibitory phosphonate compounds
JP2007508844A (ja) 2003-10-24 2007-04-12 ギリアード サイエンシーズ， インコーポレイテッド 治療用化合物の同定のための方法および組成物
US7432273B2 (en) 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
AU2004309418B2 (en) 2003-12-22 2012-01-19 Gilead Sciences, Inc. 4'-substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
SI1828167T1 (sl) * 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
DE602005027466D1 (de) 2004-07-27 2011-05-26 Gilead Sciences Inc Nukleosid phosphonat konjugate als anti hiv mittel
WO2006056794A1 (fr) 2004-11-26 2006-06-01 Ucl Business Plc Compositions contenant de l'ornithine et du phenylacetate ou du phenylbutyrate utilisee dans le traitement de l'encephalopathie hepatique
WO2007067416A2 (fr) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Agents therapeutiques et ses procédés de fabrication et d'utilisation
CA2658506C (fr) 2006-07-20 2016-01-26 Affinium Pharmaceuticals, Inc. Derives d'acrylamide en tant qu'inhibiteurs de fab 1
EP2125802A4 (fr) 2007-02-16 2014-08-20 Debiopharm Int Sa Sels, promédicaments et polymorphes d'inhibiteurs de fab 1
CN101631568B (zh) 2007-03-12 2012-08-22 尼克塔治疗公司 低聚物-蛋白酶抑制剂偶联物
EP2262538B1 (fr) * 2008-03-12 2014-12-10 Nektar Therapeutics Conjugués oligomères-acides aminés
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ阻害剤化合物の塩
PL2413924T3 (pl) * 2009-04-03 2018-02-28 Ocera Therapeutics, Inc. Fenylooctan l-ornityny i sposoby jego wytwarzania
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
NZ596916A (en) 2009-06-08 2013-09-27 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
EP2448949A1 (fr) 2009-06-30 2012-05-09 Ranbaxy Laboratories Limited Forme cristalline de fosamprénavir calcium
EP2477996A1 (fr) 2009-09-16 2012-07-25 Ranbaxy Laboratories Limited Procédé pour préparer du fosamprénavir calcium
WO2011085130A1 (fr) 2010-01-07 2011-07-14 Pliva Hrvatska D.O.O. Formes solides du sel de calcium du fosamprénavir et leur procédé de synthèse
SMT201800290T1 (it) 2010-01-27 2018-07-17 Viiv Healthcare Co Terapia antivirale
US20110224443A1 (en) * 2010-03-15 2011-09-15 Venkata Naga Brahmeshwara Rao Mandava Preparation of fosamprenavir calcium
WO2011114212A1 (fr) 2010-03-19 2011-09-22 Lupin Limited Sels d'ammonium, de calcium et de tris de fosamprénavir
US20130211108A1 (en) 2010-06-18 2013-08-15 Mylan Laboratories Ltd Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts
WO2012032389A2 (fr) 2010-09-10 2012-03-15 Lupin Limited Procédé de préparation de calcium de fosamprenavir sensiblement pur et de ses intermédiaires
CN103502203B (zh) 2010-10-06 2016-09-07 欧塞拉治疗有限公司 制备l-鸟氨酸苯基乙酸盐的方法
CN102453053B (zh) * 2010-10-29 2014-11-26 浙江九洲药业股份有限公司 一种福沙那韦钙晶体及其制备方法
CN102453054B (zh) * 2010-10-29 2015-06-10 浙江九洲药业股份有限公司 一种福沙那韦衍生物的制备方法及相关中间体
WO2012085625A1 (fr) 2010-12-21 2012-06-28 Lupin Limited Procédé pour la préparation de fosamprénavir calcique et d'un intermédiaire utilisé dans sa préparation
JP2014513044A (ja) * 2011-02-10 2014-05-29 マイラン ラボラトリーズ リミテッド ホスアンプレナビルカルシウム結晶およびその調製方法
WO2013011485A1 (fr) 2011-07-20 2013-01-24 Ranbaxy Laboratories Limited Procédé de préparation de sulfonamides utiles en tant qu'inhibiteurs de protéase rétroviraux
WO2013105118A1 (fr) 2012-01-10 2013-07-18 Council Of Scientific & Industrial Research Procédé pour la synthèse d' azido-époxyde synthétique et son utilisation en tant qu'intermédiaire de la synthèse d'amprénavir et de saquinavir
LT2861608T (lt) 2012-06-19 2019-07-10 Debiopharm International Sa (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-okso-5,6,7,8-tetrahidro-1,8-nafthidrin-3-il)akrilamido provaisto dariniai
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
WO2017031131A1 (fr) 2015-08-18 2017-02-23 Ocera Therapeutics, Inc. Traitement et prévention de la perte musculaire au moyen de l-ornithine en combinaison avec au moins un parmi l'acétate de phényle et le butyrate de phényle
WO2017144717A1 (fr) 2016-02-26 2017-08-31 Debiopharm International S.A. Médicament pour le traitement des infections du pied diabétique
US11066352B2 (en) 2017-05-11 2021-07-20 Ocera Therapeutics, Inc. Processes of making L-ornithine phenylacetate
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
CA3129508A1 (fr) 2019-02-14 2020-08-20 Debiopharm International S.A. Formulations solides d'afabicine avec de l'histidine
UA129222C2 (uk) 2019-06-14 2025-02-12 Дебіофарм Інтернешнл С.А. Лікарський засіб і його застосування для лікування бактеріальних інфекцій, пов'язаних з біоплівкою

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698826A (en) * 1951-02-13 1955-01-04 Merco Centrifugal Co Alcohol manufacturing process
US3437267A (en) * 1966-03-24 1969-04-08 Alfa Laval Ab Centrifuge
JPH0244315B2 (ja) * 1982-06-14 1990-10-03 Microbial Chem Res Found Supagarinn155hosufueetooyobisonoseizoho
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US6436989B1 (en) * 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
JP2001527062A (ja) * 1997-12-24 2001-12-25 バーテックス ファーマシューティカルズ インコーポレイテッド アスパルチルプロテアーゼインヒビターのプロドラッグ
WO1999033792A2 (fr) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Promedicaments des inhibiteurs de l'aspartyl-transferase
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
AU6329599A (en) * 1998-09-28 2000-04-17 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
EP1126847A1 (fr) * 1998-11-04 2001-08-29 PHARMACIA & UPJOHN COMPANY Methode destinee a ameliorer la pharmacocinetique du tipranavir
CZ20002364A3 (cs) * 1998-12-23 2000-11-15 Vertex Pharmaceuticals Incorporated Deriváty sulfonamidů a farmaceutický prostředek, který je obsahuje
GB9914821D0 (en) * 1999-06-24 1999-08-25 Glaxo Group Ltd Compounds
AU777824B2 (en) * 1999-11-24 2004-11-04 Merck Sharp & Dohme Corp. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1- piperazinepentanamides as HIV protease inhibitors

Also Published As

Publication number Publication date
CN1188422C (zh) 2005-02-09
HU229700B1 (en) 2014-05-28
DZ2845A1 (fr) 2003-12-01
EP1240903A3 (fr) 2003-02-12
NO329676B1 (no) 2010-11-29
IL140824A0 (en) 2002-02-10
DE69904600T2 (de) 2003-11-13
HRP20010046A2 (en) 2002-02-28
US20030096795A1 (en) 2003-05-22
YU3401A (sh) 2005-06-10
BRPI9912156B8 (pt) 2021-05-25
TR200100111T2 (tr) 2002-02-21
NO20010282D0 (no) 2001-01-17
HK1034261A1 (en) 2001-10-19
SK762001A3 (en) 2001-10-08
EE200100038A (et) 2002-06-17
ATE229964T1 (de) 2003-01-15
CZ2001219A3 (cs) 2001-07-11
PL195736B1 (pl) 2007-10-31
CN1324363A (zh) 2001-11-28
NZ509291A (en) 2003-05-30
EP1098898A1 (fr) 2001-05-16
PT1098898E (pt) 2003-04-30
JO2114B1 (en) 2000-05-21
NO20010282L (no) 2001-03-07
PA8477801A1 (es) 2000-05-24
CA2337857A1 (fr) 2000-01-27
PE20000869A1 (es) 2000-09-08
EA200100053A1 (ru) 2001-08-27
PL345620A1 (en) 2002-01-02
BR9912156A (pt) 2001-04-10
GEP20033030B (en) 2003-07-25
JP2003521447A (ja) 2003-07-15
SV1999000096A (es) 2000-07-06
DK1098898T3 (da) 2003-04-07
HUP0103432A2 (hu) 2002-04-29
KR100694721B1 (ko) 2007-03-15
CA2337857C (fr) 2011-01-25
MY122323A (en) 2006-04-29
ES2189450T3 (es) 2003-07-01
AP2001002039A0 (en) 2001-03-31
CZ300447B6 (cs) 2009-05-20
IS5808A (is) 2001-01-12
WO2000004033A1 (fr) 2000-01-27
EP1098898B1 (fr) 2002-12-18
CO5090836A1 (es) 2001-10-30
JP3437553B2 (ja) 2003-08-18
EA003191B1 (ru) 2003-02-27
ZA200100417B (en) 2002-02-27
DE69904600D1 (de) 2003-01-30
AR019388A1 (es) 2002-02-13
ID28070A (id) 2001-05-03
US6514953B1 (en) 2003-02-04
GC0000105A (en) 2005-06-29
BG105253A (en) 2001-12-29
MA26660A1 (fr) 2004-12-20
AU5037999A (en) 2000-02-07
TWI245770B (en) 2005-12-21
IL140824A (en) 2004-09-27
GB9815567D0 (en) 1998-09-16
HUP0103432A3 (en) 2003-01-28
AU766056B2 (en) 2003-10-09
KR20010071952A (ko) 2001-07-31
US20030100537A1 (en) 2003-05-29
SK285311B6 (sk) 2006-10-05
OA11706A (en) 2005-01-13
BRPI9912156B1 (pt) 2016-07-26
EP1240903A2 (fr) 2002-09-18
GT199900111A (es) 2001-01-05

Similar Documents

Publication Publication Date Title
TNSN99145A1 (fr) Calcium (3s) tetrahydro-3-furanyle (1s,2r)-3-[[4-aminophenyle) sulfonyle] isobutyle)amino]-1-benzyle-2-(phosphonooxy), propylcarbamate
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
WO2003103575A3 (fr) Composes, compositions et procedes
MA28289A1 (fr) Immunoglobulines
TNSN97010A1 (fr) Cyclopentanopyridyl-oxazolidinones contenant des heteroatomes.
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
TNSN95088A1 (fr) Benzoxazolyl - et benzothiazolyloxazolidinones
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
YU7797A (sh) Kombinovana terapija za osteoporozu
SE9704546D0 (sv) Novel compounds
AP9801269A0 (en) Prostaglandin agonists.
DE60018085D1 (de) Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
BG102660A (en) Combined pharmaceutical preparation of lhrh-analogues and antiesterogens for the treatment of gynaecological disorders
ATE221391T1 (de) Konjugat enthaltend dtpa und albumin zur individuellen dosierung von arzneimitteln
TR200000455T2 (tr) Alzheimer hastalığının tedavisinde fankinonun kullanılması.
TNSN02038A1 (fr) Composes conjugues de pregabaline et de lactose nouveaux, et compositions les contenant
BR0012921A (pt) Compostos calcilìticos
ATE415960T1 (de) Toluolsulfonamid enthaltende antitumorale zusammensetzung und anwendungsverfahren dafür
DE69718146D1 (de) At1 rezeptor antagonist zur anregung von apoptosis
TNSN00142A1 (fr) Complexe d'eletriptan et d'une sulfobutylether- betacyclodextrine, procede pour sa preparation et compositions pharmaceutiques les contenant.
DK0972521T3 (da) Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer
ATE265225T1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
CA2217463A1 (fr) Utilisation de la sulbutiamine pour l'obtention de compositions pharmaceutiques utiles dans le traitement de certains troubles psychomoteurs et psycho-intellectuels